Dr. med. Matthias Geberth

Beruflicher Werdegang

Operative und klinische Expertise

• Brusterhaltende Therapie und onkoplastische Brustchirurgie
• Sentinel-Lymphknotenbiopsie und Axilladissektion
• Mastektomie und Portimplantation
• Hysteroskopie, fraktionierte Abrasio und NovaSure
• Interdisziplinäre onkologische Therapieplanung
• Ambulante gynäkologische Operationen

Ausgewählte Publikationen

1. Schneeweiss A, et al.; Geberth M. Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor-positive, HER2-negative breast cancer – Data from the PRAEGNANT research network. The Breast. 2020;54:88–95.
2. Lux MP, et al.; Geberth M. Therapy Landscape in Patients with Metastatic HER2-Positive Breast Cancer: Data from the PRAEGNANT Real-World Breast Cancer Registry. Cancers. 2019;11(1):10.
3. Hartkopf AD, et al.; Geberth M. Treatment landscape of advanced breast cancer patients with hormone receptor-positive, HER2-negative tumors – Data from the German PRAEGNANT breast cancer registry. The Breast. 2018;37:42–51.
4. Schneeweiss A, et al.; Geberth M. First-line Bevacizumab-containing Therapy for HER2-negative Metastatic Breast Cancer: Final Results from a Prospective German Study. Anticancer Research. 2016;36(3):967–974.
5. Rugo HS, et al.; Geberth M. Incidence and time course of everolimus-related adverse events in postmenopausal women with hormone receptor-positive advanced breast cancer: insights from BOLERO-2. Annals of Oncology. 2014;25(4):808–815.
6. Beck JT, et al.; Geberth M. Everolimus plus exemestane as first-line therapy in HR-positive, HER2-negative advanced breast cancer in BOLERO-2. Breast Cancer Research and Treatment. 2014;143(3):459–467.
7. Gnant M, et al.; Geberth M. Effect of everolimus on bone marker levels and progressive disease in bone in BOLERO-2. Journal of the National Cancer Institute. 2013;105(9):654–663.
8. Kaufmann M, et al.; Geberth M. A randomised trial of goserelin versus control after adjuvant, risk-adapted chemotherapy in premenopausal patients with primary breast cancer – GABG-IV B-93. European Journal of Cancer. 2007;43(16):2351–2358.
9. von Minckwitz G, et al.; Geberth M. CMF versus goserelin as adjuvant therapy for node-negative, hormone-receptor-positive breast cancer in premenopausal patients: GABG trial IV-A-93. European Journal of Cancer. 2006;42(12):1780–1788.
10. Huhle G, Geberth M, Hoffmann U, Heene DL, Harenberg J. Management of heparin-associated thrombocytopenia in pregnancy with subcutaneous recombinant hirudin. Gynecologic and Obstetric Investigation. 2000;49(1):67–69.

Vollständige Publikations- und Kongressbeitragsliste auf Anfrage.